Mark K. Buyyounouski
Stanford University
CancerInternal medicineRadiologyUrologySurgeryOncologyArtificial intelligenceMedical physicsRadiation treatment planningBiopsyProstateBrachytherapyAndrogen deprivation therapyProstate cancerProstate-specific antigenGynecologyNuclear medicineBiochemical failureRadiation therapyMedicine
261Publications
42H-index
4,867Citations
Publications 263
Newest
#1Ting Martin Ma (UCLA: University of California, Los Angeles)H-Index: 10
#2Soumyajit Roy (Rush University Medical Center)
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 22
view all 27 authors...
Background and purpose null The Phoenix definition for biochemical failure (BCF) after radiotherapy uses nadir PSA (nPSA)+2ng/mL to classify a BCF and was derived from conventionally fractionated radiotherapy, which produces significantly higher nPSAs than stereotactic body radiotherapy (SBRT). We investigated whether an alternative nPSA-based threshold could be used to define post-SBRT BCFs. null Materials and methods null PSA kinetics data on 2038 patients from 9 institutions were retrospectiv...
Source
Purpose/Objective(s) null Propagation of contours from high-quality magnetic resonance (MR) images to treatment planning ultrasound (US) images with severe needle artifacts is a challenging task, which can greatly aid the organ or intraprostatic lesion contouring in high dose rate (HDR) prostate brachytherapy. In this study, a deep learning approach was developed to automatize this registration procedure for HDR brachytherapy practice. null null null Materials/Methods null With the approval from...
Source
#1Mark K. Buyyounouski (Stanford University)H-Index: 42
#2Stephanie L. PughH-Index: 24
Last. Richard K. Valicenti (UC Davis: University of California, Davis)H-Index: 43
view all 20 authors...
PURPOSE/OBJECTIVE(S) To determine if hypofractionated post-operative prostate bed radiotherapy (HYPORT) does not increase patient-reported genitourinary (GU) or gastrointestinal (GI) toxicity over conventionally fractionated post-operative radiotherapy (COPORT). MATERIALS/METHODS Eligibility criteria were: 1) an undetectable PSA (< 0.1 ng/mL) with either margin negative pT3pN0/X or margin positive pT2pN0/X adenocarcinoma of the prostate or 2) a detectable PSA (≥ 0.1 ng/mL) and pT2/3pN0/X disease...
Source
#1Yizheng Chen (Stanford University)H-Index: 2
#3Lu Yu (Stanford University)H-Index: 11
Purpose/Objective(s) null Contouring organs at risk (OARs) is a key step of radiotherapy treatment planning. In this study, a deep learning-based framework was developed to automatize the whole OAR contouring process contributing to the clinical practice. null null null Materials/Methods null This auto-segmentation framework consisted of a pre-processing module, a deep learning-based segmentation module, and a post-processing module. We focused on the auto-segmentation in head and neck, and pelv...
Source
#1Ting Martin Ma (UCLA: University of California, Los Angeles)H-Index: 10
#2Soumyajit Roy (NYMC: New York Medical College)H-Index: 10
Last. Rachel Glicksman (U of T: University of Toronto)H-Index: 7
view all 20 authors...
Purpose/Objective(s) null Since the seminal Phoenix definition (nadir PSA+2) of biochemical failure (BCF) was published in 2006, increasingly more patients with low- and intermediate-risk prostate cancer (PCa) are being treated with stereotactic body radiation therapy (SBRT). Since SBRT leads to lower nadir PSA (nPSA) compared to conventionally fractionated RT, we investigated if an earlier nPSA+threshold can be used as an alternative definition of BCF. null null null Materials/Methods null PSA ...
Source
#1Jesus E. Juarez (UCLA Medical Center)H-Index: 4
#2Tahmineh Romero (UCLA: University of California, Los Angeles)H-Index: 7
Last. Irving D. KaplanH-Index: 52
view all 21 authors...
ABSTRACT null null Purpose null To evaluate the safety of stereotactic body radiotherapy (SBRT) for prostate cancer in men with inflammatory bowel disease (IBD). null null null Methods and Materials null We queried a consortium database for patients with IBD receiving SBRT for prostate cancer between 2006-2012. Identified patients were matched with patients without a history of IBD in a 3:1 fashion based on dose, fractionation, use of androgen deprivation therapy, and age distribution. Logistic ...
Source
#5John T. Leppert (Stanford University)H-Index: 31
Prostate cancer treatment strategies are guided by risk-stratification. This stratification can be difficult in some patients with known comorbidities. New models are needed to guide strategies and determine which patients are at risk of prostate cancer mortality. This article presents a gradient-boosting model to predict the risk of prostate cancer mortality within 10 years after a cancer diagnosis, and to provide an interpretable prediction. This work uses prospective data from the PLCO Cancer...
Source
PURPOSE Propagation of contours from high-quality magnetic resonance (MR) images to treatment planning ultrasound (US) images with severe needle artifacts is a challenging task, which can greatly aid the organ contouring in high dose rate (HDR) prostate brachytherapy. In this study, a deep learning approach was developed to automatize this registration procedure for HDR brachytherapy practice. METHODS Because of the lack of training labels and difficulty of accurate registration from inferior im...
Source
#6Yan Chen (Stanford University)H-Index: 4
PURPOSE To develop and evaluate a deep unsupervised learning (DUL) framework based on a regional deformable model for automated prostate contour propagation from planning computed tomography (pCT) to cone-beam CT (CBCT). METHODS We introduce a DUL model to map the prostate contour from pCT to on-treatment CBCT. The DUL framework used a regional deformable model via narrow band mapping to augment the conventional strategy. 251 anonymized CBCT images from prostate cancer patients were retrospectiv...
Source
#1Lucia Baratto (Stanford University)H-Index: 11
#2Hong Song (Stanford University)H-Index: 3
Last. Andrei Iagaru (Stanford University)H-Index: 40
view all 13 authors...
Rationale: Novel radiopharmaceuticals for positron emission tomography (PET) are evaluated for the diagnosis of biochemically recurrent prostate cancer (BCR PC). Here, we compare the gastrin releasing peptide receptors (GRPR) - targeting 68Ga-RM2 with the prostate specific membrane antigen (PSMA) – targeting 68Ga-PSMA11 and 18F-DCFPyL. Methods: Fifty patients had both 68Ga-RM2 PET/MRI and 68Ga-PSMA11 PET/CT (n = 23) or 18F-DCFPyL PET/CT (n = 27) at an interval ranging from 1 to 60 days (mean±SD:...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.